Entropy Technologies LP Has $2.19 Million Holdings in STERIS plc $STE

Entropy Technologies LP lessened its position in shares of STERIS plc (NYSE:STE) by 25.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,899 shares of the medical equipment provider’s stock after selling 3,398 shares during the period. Entropy Technologies LP’s holdings in STERIS were worth $2,189,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund boosted its position in STERIS by 58.8% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 6,161 shares of the medical equipment provider’s stock valued at $1,362,000 after acquiring an additional 2,282 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in shares of STERIS by 3.0% in the 1st quarter. Public Employees Retirement System of Ohio now owns 57,779 shares of the medical equipment provider’s stock worth $12,777,000 after acquiring an additional 1,692 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of STERIS by 20.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 519,511 shares of the medical equipment provider’s stock valued at $114,879,000 after purchasing an additional 88,872 shares during the period. Inceptionr LLC acquired a new position in shares of STERIS in the 1st quarter valued at about $839,000. Finally, Gibbs Wealth Management boosted its position in shares of STERIS by 143.8% during the 1st quarter. Gibbs Wealth Management now owns 2,345 shares of the medical equipment provider’s stock valued at $519,000 after purchasing an additional 1,383 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on STE. KeyCorp decreased their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Piper Sandler restated an “overweight” rating and set a $270.00 price target on shares of STERIS in a report on Thursday, May 21st. Finally, Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Insider Transactions at STERIS

In related news, CEO Daniel A. Carestio sold 3,054 shares of STERIS stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $214.64, for a total value of $655,510.56. Following the completion of the sale, the chief executive officer owned 65,021 shares of the company’s stock, valued at approximately $13,956,107.44. This trade represents a 4.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the sale, the director owned 38,964 shares of the company’s stock, valued at $8,163,347.64. This trade represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 7,328 shares of company stock valued at $1,554,051 over the last ninety days. 1.12% of the stock is owned by company insiders.

STERIS Price Performance

STE stock opened at $214.16 on Monday. The stock has a market capitalization of $20.87 billion, a PE ratio of 27.01 and a beta of 0.92. The company’s 50-day moving average is $211.69 and its 200-day moving average is $227.40. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. STERIS plc has a 1 year low of $195.14 and a 1 year high of $269.44.

STERIS (NYSE:STE) last issued its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the previous year, the firm earned $2.74 earnings per share. The business’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities research analysts expect that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Stockholders of record on Monday, June 8th were issued a dividend of $0.63 per share. The ex-dividend date was Monday, June 8th. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. STERIS’s payout ratio is currently 31.78%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.